RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental drug GSK5926371 enters human trials
Disease control Not yet recruitingThis early-stage trial tests a new drug called GSK5926371 in about 49 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Researchers will also …
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cell therapy B019 takes on tough lymphoma in first human trial
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC